Telix Pharmaceuticals strong pipeline

Telix Pharmaceuticals has continued to report strong commercial growth along with pipeline progress while the stock now trades at a much more compelling valuation compared to its historical levels.

Telix Pharmaceuticals Limited (ASX: TLX)

on April 14 2026 announced that it had successfully priced and increased its convertible bond offering from US$550 million to US$600 million helped by strong demand from global investors. This reflected the high confidence in the company’s long term growth outlook.

The company said the new convertible bonds have a relatively low coupon rate of 1.50% per annum and will mature in 2031. Most of the proceeds are expected to be used for refinancing existing debt and improving financial flexibility.

The stock has fallen 45.3% over the past 12 months which has brought the company to more compelling valuation levels. Telix at the time of writing has a market capitalisation of about $4.78 billion. The large decline in the share price came despite the business having reported very strong commercial growth along with pipeline progress and better operational execution.

Impressive revenue growth

The company in 2025 reported that group revenue jumped 56% year-on-year to US$804 million while Precision Medicine revenue rose 22% to US$622 million.
Telix also reported positive Group EBITDA of US$40 million and finished the year with a positive cash balance of US$142 million. 

The company generated group revenue of US$230 million in Q1 2026 which represented 11% sequential growth compared with the previous quarter. Management stated that its two-product strategy has supported strong growth because Illuccix and Gozellix continue to gain market share across major global markets.

Telix also highlighted that its products are now commercially available in 22 countries while expansion efforts continue across China along with Japan and Europe.

The company has a vertically integrated radiopharmaceutical business model which includes research and development along with manufacturing and a growing global supply chain network. This structure could become a major competitive advantage over time because it will be difficult for competitors to replicate.

Long-term growth drivers

Another major reason investors remain interested in Telix is the company’s large pipeline of oncology focused radiopharmaceutical assets. 

Management believes the company’s long term market opportunity across its Precision Medicine and Therapeutics portfolio could eventually exceed US$32 billion.
One of the most important upcoming catalysts is Pixclara which targets recurrent glioblastoma. Telix announced that the U.S. FDA assigned a PDUFA goal date of September 11 2026 for the product candidate.

Management also stated that in a survey of 100 physicians around 70% of surveyed U.S. doctors indicated they are ready to prescribe Pixclara if it receives approval. 
Another major recent development was Telix’s strategic collaboration with Regeneron.  Telix under this agreement could receive US$40 million upfront and potentially up to US$2.1 billion in development and commercial milestone payments along with future royalties.

The partnership focuses on developing next generation radiopharmaceutical therapies that target multiple solid tumours. 

Outlook

Telix expects full year group revenue between US$950 million and US$970 million which is supported by approximately 25% growth in Precision Medicine revenue.

The company also plans to keep investing heavily into research and development as FY2026 R&D expenditure guidance currently is between US$200 million and US$240 million.

Telix’s 2026 roadmap is rich with catalysts because the company expects numerous clinical trial updates along with regulatory decisions and commercial launches throughout the year.

(Source: Company Announcements)